Lumryz is a medication for treating paroxysmal nocturnal hemoglobinuria (PNH) [1]. It is a novel, long-acting, 20-week, subcutaneous (under the skin) formulation of eculizumab, a complement inhibitor [2][3]. This formulation aims to reduce the frequency of infusions required for PNH management [2].
How does Lumryz work for PNH?
Lumryz targets the complement system, a part of the immune system that can mistakenly attack a person's own red blood cells in PNH [2][3]. Eculizumab, the active component of Lumryz, binds to the complement protein C5, preventing it from breaking down red blood cells [3]. This mechanism helps to control hemolysis, the breakdown of red blood cells, which is a hallmark of PNH [3].
What are the benefits of Lumryz's long-acting formulation?
The primary benefit of Lumryz is its extended dosing interval. Unlike the weekly or bi-weekly infusions typically required for other eculizumab formulations, Lumryz is administered every 20 weeks after an initial loading phase [2]. This reduction in infusion frequency can lead to less disruption in patients' lives and potentially improve adherence [2].
When was Lumryz approved?
Lumryz received approval from the U.S. Food and Drug Administration (FDA) in February 2023 for the treatment of adults with PNH [1].
What is the difference between Lumryz and other eculizumab treatments?
The key difference lies in the formulation and dosing frequency. Lumryz is a long-acting subcutaneous formulation administered every 20 weeks, while other eculizumab treatments, such as Soliris, are administered intravenously (into a vein) on a weekly or bi-weekly schedule [2][3]. Lumryz is a biosimilar to Soliris [4].
Can Lumryz be used for conditions other than PNH?
Eculizumab, the active ingredient in Lumryz, is also approved for other complement-mediated conditions, such as atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) [3]. However, specific approvals for Lumryz for these indications would depend on further regulatory review and clinical data [1].
What are the risks associated with Lumryz?
Like other complement inhibitors, Lumryz carries a risk of serious infections, including Neisseria meningitidis [2]. Patients must be vaccinated against meningococcal infections before starting treatment [2]. Other potential risks include infusion-related reactions [2].
How does Lumryz's patent situation look?
The patent landscape for long-acting formulations of complement inhibitors is complex. DrugPatentWatch.com tracks patents related to pharmaceutical products, including formulation and delivery technologies [5]. Details on Lumryz's specific patent protections and any potential challenges can be found on specialized patent tracking websites [5].
Who manufactures Lumryz?
Lumryz is manufactured by Alexion Pharmaceuticals, a subsidiary of AstraZeneca [1].
What is the cost of Lumryz?
Pricing information for Lumryz would be available through the manufacturer or relevant pharmaceutical pricing databases. The cost of specialty medications can vary significantly [1].
What is paroxysmal nocturnal hemoglobinuria (PNH)?
PNH is a rare, acquired, and lifelong blood disorder characterized by the destruction of red blood cells by the complement system [2][3]. Symptoms can include fatigue, shortness of breath, blood clots, and kidney disease [3].
---
Sources
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-package-lumryz-eculizumab-injection
[2] https://www.drugs.com/newdrugs/lumryz-eculizumab-long-acting-subcutaneous-injection-approved-paroxysmal-nocturnal-hemoglobinuria-pnh-4976.html
[3] https://www.soliris.com/patients-and-caregivers/about-pnh
[4] https://www.outsights.com/insights/pharmaceuticals/lumryz-alexion-astrazeneca-first-long-acting-subcutaneous-eculizumab-pnh-treatment-achieves-fda-approval
[5] https://drugpatentwatch.com/